2026 Scott J. Antonia: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	102	7470	7018	3905	3611	448	87137

Overview

Scott J. Antonia is affiliated with Duke University in the United States. Their research primarily focuses on the field of Medicine, with a significant concentration in Oncology, Pulmonary and Respiratory Medicine, Immunology, Cancer Research, and Molecular Biology.

Their main research topics encompass:

Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations
CAR-T cell therapy research
Lung Cancer Research Studies
Immunotherapy and Immune Responses
Colorectal Cancer Treatments and Studies
Lung Cancer Diagnosis and Treatment

Scott J. Antonia has frequently published in the following journals:

Journal of Clinical Oncology
Cancer Research
Journal of Thoracic Oncology
Annals of Oncology
Lung Cancer

Recent notable papers authored include:

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial (2021, The Lancet)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer (2020, JAMA Oncology)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (2021, Journal of Clinical Oncology)
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial (2021, Journal of Thoracic Oncology)
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial (2021, Nature Medicine)

The scientist has collaborated frequently with several co-authors, including:

Jhanelle E. Gray
Amer A. Beg
Ben Creelan
Neal Ready
José R. Conejo-García

Best Publications

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

14371
Citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

9411
Citations
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

8692
Citations
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott J Antonia;Augusto Villegas;Davey Daniel;David Vicente

3962
Citations
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott J. Antonia;Augusto Villegas;Davey Daniel;David Vicente

2538
Citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

1855
Citations
Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses

Paulo C. Rodriguez;David G. Quiceno;Jovanny Zabaleta;Blair Ortiz

1445
Citations
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

1382
Citations
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

1342
Citations
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

David H. Munn;Madhav D. Sharma;Jeffrey R. Lee;Kanchan G. Jhaver

1331
Citations
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Matthew D. Hellmann;Tavi Nathanson;Hira Rizvi;Benjamin C. Creelan

1108
Citations
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

David H. Munn;Madhav D. Sharma;Deyan Hou;Babak Baban

1094
Citations
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez

1039
Citations
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

976
Citations
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

946
Citations
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Paul Baas;Arnaud Scherpereel;Anna K Nowak;Nobukazu Fujimoto

854
Citations
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Matthew D. Hellmann;Margaret K. Callahan;Mark M. Awad;Emiliano Calvo

806
Citations
Lipid accumulation and dendritic cell dysfunction in cancer

Donna L. Herber;Wei Cao;Yulia Nefedova;Sergey V. Novitskiy

731
Citations
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Scott Gettinger;Leora Horn;David Jackman;David Spigel

681
Citations
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

Noweeda Mirza;Mayer Fishman;Ingo Fricke;Mary Dunn

657
Citations

Frequent Co-Authors

Julie R. Brahmer Johns Hopkins University

Eric B. Haura University of South Florida

Naiyer A. Rizvi Columbia University Medical Center

Scott N. Gettinger Yale University

David R. Spigel Sarah Cannon Research Institute

Leora Horn Vanderbilt University Medical Center

Dmitry I. Gabrilovich AstraZeneca (United Kingdom)

Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

Luis Paz-Ares Complutense University of Madrid

David Planchard Institut Gustave Roussy

External Links

Personal website of Scott J. Antonia

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a range of complementary online degrees and advanced career pathways in healthcare. For those interested in the administrative side, pursuing one of the best online mha programs is a flexible option to develop management and leadership skills specific to medical settings.

Affordability is another key concern for aspiring professionals. If cost is an important factor, consider enrolling in the cheapest master’s in healthcare administration programs, which combine quality education with budget-friendly tuition.

Advanced practice roles are also within reach through specialized online doctorates. Nurses aiming to reach the highest clinical ranks can benefit from the best online dnp programs, providing doctoral-level expertise in nursing practice and leadership.

For those passionate about medication therapy and patient care, pharmacy is a rewarding path to consider. Earning an online pharmacy degree offers a flexible way to gain credentials and advance your pharmaceutical career.